Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
McKesson
Express Scripts
Johnson and Johnson
Boehringer Ingelheim

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for SJG-136

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug SJG-136: Patents, clinical trial progress, indications

SJG-136 is an investigational drug.

There have been 4 clinical trials for SJG-136. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2010.

The most common disease conditions in clinical trials are Neoplasm Metastasis, Ovarian Neoplasms, and Leukemia. The leading clinical trial sponsors are National Cancer Institute (NCI) and [disabled in preview].

There are forty-nine US patents protecting this investigational drug and five hundred and forty-five international patents.

Recent Clinical Trials for SJG-136
TitleSponsorPhase
SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or CarboplatinNational Cancer Institute (NCI)Phase 2
SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic LeukemiaNational Cancer Institute (NCI)Phase 1
SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By SurgeryNational Cancer Institute (NCI)Phase 1

See all SJG-136 clinical trials

Clinical Trial Summary for SJG-136

Top disease conditions for SJG-136
Top clinical trial sponsors for SJG-136

See all SJG-136 clinical trials

US Patents for SJG-136

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SJG-136   Start Trial Pyrrolobenzodiazepine-antibody conjugates Medimmune Limited (Cambridge, GB)   Start Trial
SJG-136   Start Trial Anti-CS1 antibodies and antibody drug conjugates AbbVie Biotherapeutics Inc. (Redwood City, CA)   Start Trial
SJG-136   Start Trial Humanized anti-Tn-MUC1 antibodies and their conjugates ADC Therpeutics S.A. (Epalinges, CH) Medimmune Limited (Cambridge, GB)   Start Trial
SJG-136   Start Trial Pyrrolobenzodiazepines and conjugates thereof MEDIMMUNE LIMITED (Cambridge, GB)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for SJG-136

Drugname Country Document Number Estimated Expiration Related US Patent
SJG-136 Australia 2014333762 2033-10-11   Start Trial
SJG-136 Australia 2014333763 2033-10-11   Start Trial
SJG-136 Canada 2926876 2033-10-11   Start Trial
SJG-136 China 105636613 2033-10-11   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Merck
AstraZeneca
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.